Home › Calculator › ANRO Dividend Calculator 2026
ANRO Dividend Calculator 2026
No dividendHealthcareAlto Neuroscience, Inc. · NYSE
Price: $21.95 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
ANRO is not a dividend-focused stock
ANRO pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
ANRO Dividend Yield
Alto Neuroscience, Inc. (ANRO) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ANRO pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Alto Neuroscience, Inc. (ANRO) — Dividend Analysis 2026
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
ANRO Dividend & DRIP — Frequently Asked Questions
Does ANRO pay a dividend?
No. Alto Neuroscience, Inc. (ANRO) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of ANRO?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does ANRO have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. ANRO has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to ANRO
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ANRO DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ANRO position with:
🌍 ANRO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ANRO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ANRO Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ANRO Dividend Payment Schedule
ANRO pays quarterly — 4 times per year. Ex-div: —.
📊 ANRO vs Healthcare Benchmarks
How ANRO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ANRO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ANRO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-10-02 | 55,000 | $2.32 | $127.6K | ||
| M-Exempt | 2026-10-02 | 55,000 | $2.32 | $127.6K | ||
| M-Exempt | 2026-09-29 | 56,455 | $2.35 | $132.7K | ||
| M-Exempt | 2026-09-29 | 54,375 | $2.35 | $127.8K | ||
| M-Exempt | 2026-09-30 | 24,056 | $2.35 | $56.5K | ||
| M-Exempt | 2026-09-29 | 56,455 | $2.35 | $132.7K | ||
| M-Exempt | 2026-09-30 | 24,056 | $2.35 | $56.5K | ||
| M-Exempt | 2026-09-29 | 54,375 | $2.35 | $127.8K | ||
| Sale | 2026-09-30 | 23,170 | $25.78 | $597.3K | ||
| Sale | 2026-09-30 | 886 | $26.87 | $23.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare ANRO with peers: ANRO vs ACIU · ANRO vs ALDX · ANRO vs AMRN
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ANRO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Alto Neuroscience, Inc. (ANRO) is currently trading at $21.95, 41% below its 52-week high. It does not currently pay a regular dividend.
Does ANRO Pay a Dividend? Alto Neuroscience, Inc. Dividend Status
Alto Neuroscience, Inc. (ANRO) is a healthcare stock trading at $21.95. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ANRO News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
Projected your ANRO DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.